Oncology Nursing News®

Register now to learn about a new option for relapsed or refractory follicular lymphoma

Childhood/AYA Cancer

FDA Approves Pralsetinib for RET-Altered Thyroid Cancers

FDA Approves Pralsetinib for RET-Altered Thyroid Cancers

BY BRIELLE BENYON

FDA Approves Naxitamab-gqgk for Pediatric and Adult High-Risk Neuroblastoma

FDA Approves Naxitamab-gqgk for Pediatric and Adult High-Risk Neuroblastoma

BY GINA MAURO

Capturing the Voice of the Child in Cancer Care

Capturing the Voice of the Child in Cancer Care

BY BRIELLE BENYON

A Smiling Nurse Makes All the Difference in Pediatric Oncology

A Smiling Nurse Makes All the Difference in Pediatric Oncology

BY BRIELLE BENYON

Pediatric Osteosarcoma and Pathogenic TP53 Variants

Pediatric Osteosarcoma and Pathogenic TP53 Variants

BY CAROLINE SEYMOUR

Nivatrotamab Granted Orphan Drug Status for Pediatric Neuroblastoma

Nivatrotamab Granted Orphan Drug Status for Pediatric Neuroblastoma

BY KRISTI ROSA

FDA Grants Priority Review to Crizotinib for Pediatric ALK-Positive ALCL

FDA Grants Priority Review to Crizotinib for Pediatric ALK-Positive ALCL

BY KRISTI ROSA

Nurses Develop New Measure for Pediatric CIPN

Nurses Develop New Measure for Pediatric CIPN

BY BRIELLE BENYON

Blinatumomab: New Standard of Care for Pediatric, High-Risk ALL

Blinatumomab: New Standard of Care for Pediatric, High-Risk ALL

BY KRISTI ROSA

FDA in Favor of Remestemcel-L for Pediatric GVHD

FDA in Favor of Remestemcel-L for Pediatric GVHD

BY KRISTI ROSA

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.